Inventiva secures EUR230.9M cash ahead of delayed Q4 2026 NATIV-3 readout
Inventiva reports sub-30% dropout in NATIV-3 with 800mg dose projected to match 1,200mg tolerability over time and aims for 18% fibrosis improvement in F3 diabetic MASH patients. The top-line readout has been pushed to Q4 2026, with funding tranches tied to positive results and EUR230.9M cash on hand.
1. NATIV-3 Trial Update
Inventiva’s NATIV-3 trial currently shows a dropout rate below 30%, ensuring over 90% power for the primary endpoint. Early indications suggest the 800mg dose may catch up to the 1,200mg dose in efficacy, with potential tolerability advantages, while the top-line readout is now expected in Q4 2026 and further financing is contingent on positive data.
2. Market and Competition
Lanifibranor targets an estimated 375,000 under-treated F3 diabetic MASH patients, aiming for an 18% fibrosis improvement threshold to secure market positioning. Madrigal’s strong US uptake presents competition, and with only 10% of the 18 million US MASH cases diagnosed, there remains significant unmet need.
3. Financial Position and Leadership
The company holds EUR230.9 million in cash equivalents and short-term deposits, providing runway beyond the delayed readout. Recent key leadership appointments support a strategic focus on lanifibranor, which has received both breakthrough therapy and fast-track designations from the FDA.